Validation of the Freezing of Gait Questionnaire in patients with Parkinson's disease

Movement Disorders

Volumn 24, Issue 5, 2009, Pages 655-661

  Giladi, Nir ^a   Tal, Joseph ^b   Azulay, Tali ^b   Rascol, Oliver ^c   Brooks, David J ^d   Melamed, Eldad ^a   Oertel, Wolfgang ^e   Poewe, Werner H ^f   Stocchi, Fabrizio ^g   Tolosa, Eduardo ^h  

^a TEL AVIV UNIVERSITY   (Israel)

^b TechnoStat Ltd   (Israel)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f UNIVERSITY OF INNSBRUCK   (Austria)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h HOSPITAL CLÍNIC   (Spain)

Author keywords

Freezing of gait; Parkinson's disease; Rasagiline; Validation

Indexed keywords

ENTACAPONE; LEVODOPA; PLACEBO; RASAGILINE; ANTIPARKINSON AGENT; CATECHOL DERIVATIVE; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT; NITRILE;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FREEZING OF GAIT QUESTIONNAIRE; GAIT DISORDER; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PARKINSON DISEASE QUESTIONNAIRE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TEST RETEST RELIABILITY; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; VALIDITY; ANALYSIS OF VARIANCE; CATALEPSY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HOSPITALIZATION; MIDDLE AGED; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; REPRODUCIBILITY; STATISTICS; VALIDATION STUDY;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; CATECHOLS; DOUBLE-BLIND METHOD; FEMALE; FREEZING REACTION, CATALEPTIC; GAIT DISORDERS, NEUROLOGIC; HUMANS; INDANS; LEVODOPA; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NITRILES; PARKINSON DISEASE; PRINCIPAL COMPONENT ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC;

EID: 67651171544     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21745     Document Type: Article

References (24)

1. Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 2004;19:871-884.
2. Giladi N. Freezing of gait, clinical overview. Adv Neurol 2001; 87:191-197.
3. Nieuwboer A, de Weerdt W, Dom R, Lesaffre E. A frequency and correlation analysis of motor deficits in Parkinson patients. Disabil Rehabil 1998;20:142-150.
4. Giladi N, McMahon D, Przedborski S, et al. Motor blocks in Parkinson's disease. Neurology 1992;42:333-339.
5. Giladi N, McDermott MP, Fahn S, et al, on behalf of the Parkinson Study Group. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001;56:1712-1721.
6. Schaafsma JD, Balash Y, Gurevich, Bartels AL, Hausdorff JM, Giladi N. Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease. Eur J Neurol 2003;10:391-398.
7. Giladi N, Shabtai H, Simon ES, Biran S, Tal J, Korczyn AD. Construction of freezing of gait questionnaire for patients with parkinsonism. Parkinsonism Relat Disord 2000;6:165-170.
8. Rascol O, Brooks DJ, Melamed E, et al., for the LARGO Study Group. Rasagiline as an adjunct to levodopa in Parkinson's disease patients with motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial. Lancet 2005;365:947-954.
9. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
10. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020-1028.
11. Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease. Macmillan: Florham Park, NJ; 1987. p 153-164.
12. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psych 1961;4:561-571.
13. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995;4:241-248.
14. Giladi N, Fahn S. Freezing phenomenon, the fifth cardinal sign of parkinsonism. In: Fisher A, Hanin I, Yoshida M, editors. Progress in Alzheimer's and Parkinson's Diseases. Plenum Press: New York; 1998. P 329-335.
15. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE for The 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
16. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
17. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-11934.
18. Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007;78:134-140.
19. Gurevich T, Peretz C, Moore O, Weizmann N, Giladi N. The effect of injecting botulinum toxin type A into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study. Mov Disord 2007;22:880-883.
20. Giladi N, Gurevich T, Shabtai H, Paleacu D, Simon ES. The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J Neurol 2001;248:572-576.
21. Shoulson I, Oakes D, Fahn S, et al, on behalf of the Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-612.
22. Holloway RG, Shoulson I, Fahn S, et al; Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053, Erratum in: Arch Neurol 2005;62:430.
23. Giladi N, Treves TA, Simon ES, et al. Freezing of gait in patients with advanced Parkinson's disease. J Neural Transm 2001;108:53-61.
24. Nieuwboer A, Herman T, Rochester L, Giladi N. Evaluation of freezing of gait severity in patients with Parkinson's disease; the perception of caregivers. Mov Disord 2006;21 (Suppl):607.